Monteris Medical, a provider of image-guided laser interstitial thermal therapy (LITT), has announced the commercial launch of its NeuroBlate NB3 FullFire 1.6mm laser probe.

The new NB3 laser probe is the company’s latest product for use with its NeuroBlate System, a minimally invasive system that enables a robotic interface for the delivery of laser energy.

NeuroBlate System is a neurosurgical tool intended for ablating intracranial soft tissue, including brain structures such as brain tumours, radiation necrosis, and epileptic foci.

The new laser probe features the NeuroBlate System’s patented cooling technology and incorporates the latest advancements in laser fibre technology.

Monteris said that the NB3 is the smallest laser probe commercially available for use in the brain and is available in a single adjustable length.

In addition, the single NB3 probe offers economic value to hospitals and simplifies inventory management with a single product, said the medical device maker.

Monteris president and CEO Martin Emerson said: “We are thrilled to bring the highly anticipated NB3 laser probe to our neurosurgeons and hospital system customers for use across a broad spectrum of patient needs, including the paediatric LITT population.

“NB3, used in combination with Monteris’ best-in-class NeuroBlate software and robotics, provides our neurosurgeon users the precision and flexibility they demand for their patients.

“We expect the forward-thinking engineering incorporated into NB3 will become the platform for our future probe designs. In addition, our near-term cadence of new software releases will put even greater options in the hands of our neurosurgeon customers.”

The NB3 laser probe received the US Food and Drug Administration (FDA) 510(k) approval in December last year and has been in limited market release in the US since February this year.

The laser probe has been used by the surgeons in the initial launch phase, across a wide set of workflows, lesion types, sizes, locations, target depths and patient profiles.

Different lesion types include primary tumours, progressive metastatic lesions, radiation necrosis and epileptogenic foci in both adult and paediatric patients.

The laser probe was also used for ablating different lesion sizes ranging from less than 10mm to nearly 30mm in diameter, including deep-seated targets and multiple trajectory procedures.

The new NB3 probe can be used at varying power settings ranging from six to 12 watts and is engineered to deliver small to large ablations, said the medical technology company.